Portal de Periódicos da CAPES

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

2017; Elsevier BV; Volume: 28; Linguagem: Inglês

10.1093/annonc/mdx449

1569-8041

Michael A. Bookman, Aikou Okamoto, Gavin Stuart, Nozomu Yanaihara, Daisuke Aoki, Monica Bacon, Keiichi Fujiwara, Antonio González‐Martín, P. Harter, Jae‐Weon Kim, Jonathan A. Ledermann, Éric Pujade-Lauraine, Michael Quinn, Kazunori Ochiai,

Cancer Genomics and Diagnostics

The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.